Please try another search
QIAGEN N.V. (NYSE: QGEN) reported a 5% decline in net sales for the first quarter of 2024, totaling $462 million at constant exchange rates, compared to the same period last year. Despite this, the...
VENLO, the Netherlands - Qiagen N.V. (NYSE: NYSE:QGEN) reported first-quarter earnings that edged past analysts' expectations but provided a full-year outlook that fell short of consensus estimates,...
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date...
Qiagen NV (NYSE:QGEN) reported a robust fourth quarter for 2023, surpassing its own financial outlook with net sales reaching $503 million and an adjusted EPS of $0.55, exceeding the projected $0.53....
QIAGEN's Q3 2023 earnings call underscored a robust performance, with net sales reaching $470 million at constant exchange rates (CER), surpassing expectations despite a volatile macroeconomic...
QIAGEN N.V. (NYSE:QGEN), the Dutch biotechnology company, reported a decrease in earnings for the third quarter of 2023, despite surpassing market expectations. The company's adjusted earnings per...
Qiagen (QGEN) reported Q1 EPS of $0.53, $0.06 better than the analyst estimate of $0.47. Revenue for the quarter came in at $498 million versus the consensus estimate of $489.92 million.
Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review